These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21083013)

  • 1. Clinical activity of laromustine (Onrigin™) in hematologic malignancies.
    Alvarado Y; Swords R; Kelly KR; Giles FJ
    Expert Rev Hematol; 2009 Oct; 2(5):481-8. PubMed ID: 21083013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy.
    Pigneux A
    IDrugs; 2009 Jan; 12(1):39-53. PubMed ID: 19127504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-dependent general base catalyzed activation rather than isocyanate liberation may explain the superior anticancer efficacy of laromustine compared to related 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)hydrazine prodrugs.
    Penketh PG; Finch RA; Sauro R; Baumann RP; Ratner ES; Shyam K
    Chem Biol Drug Des; 2018 Jan; 91(1):62-74. PubMed ID: 28636806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
    Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
    Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laromustine (cloretazine).
    Vey N; Giles F
    Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation.
    Baumann RP; Seow HA; Shyam K; Penketh PG; Sartorelli AC
    Oncol Res; 2005; 15(6):313-25. PubMed ID: 16408696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients.
    Nassar AF; Wisnewski AV; King I
    Xenobiotica; 2017 May; 47(5):394-407. PubMed ID: 27440490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
    Schiller GJ; O'Brien SM; Pigneux A; Deangelo DJ; Vey N; Kell J; Solomon S; Stuart RK; Karsten V; Cahill AL; Albitar MX; Giles FJ
    J Clin Oncol; 2010 Feb; 28(5):815-21. PubMed ID: 20026800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cloretazine for the treatment of acute myeloid leukemia.
    Vey N; Giles F
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative relationship between guanine O(6)-alkyl lesions produced by Onrigin™ and tumor resistance by O(6)-alkylguanine-DNA alkyltransferase.
    Ishiguro K; Zhu YL; Shyam K; Penketh PG; Baumann RP; Sartorelli AC
    Biochem Pharmacol; 2010 Nov; 80(9):1317-25. PubMed ID: 20654586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
    Giles F; Rizzieri D; Karp J; Vey N; Ravandi F; Faderl S; Khan KD; Verhoef G; Wijermans P; Advani A; Roboz G; Kantarjian H; Bilgrami SF; Ferrant A; Daenen SM; Karsten V; Cahill A; Albitar M; Mufti G; O'Brien S
    J Clin Oncol; 2007 Jan; 25(1):25-31. PubMed ID: 17146105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thioredoxin reductase is inhibited by the carbamoylating activity of the anticancer sulfonylhydrazine drug laromustine.
    Rice KP; Klinkerch EJ; Gerber SA; Schleicher TR; Kraus TJ; Buros CM
    Mol Cell Biochem; 2012 Nov; 370(1-2):199-207. PubMed ID: 22864532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
    Badruddoja MA; Penne K; Desjardins A; Reardon DA; Rich JN; Quinn JA; Sathornsumetee S; Friedman AH; Bigner DD; Herndon JE; Cahill A; Friedman HS; Vredenburgh JJ
    Neuro Oncol; 2007 Jan; 9(1):70-4. PubMed ID: 17108065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.
    Rockwell S; Liu Y; Seow HA; Ishiguro K; Baumann RP; Penketh PG; Shyam K; Akintujoye OM; Glazer PM; Sartorelli AC
    Int J Radiat Biol; 2012 Mar; 88(3):277-85. PubMed ID: 22111842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).
    Nassar AE; King I; Du J
    Chem Res Toxicol; 2011 Apr; 24(4):568-78. PubMed ID: 21361357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
    Keir ST; Morton CL; Billups C; Smith MA; Houghton PJ; Gururangan S
    Pediatr Blood Cancer; 2008 Sep; 51(3):439-41. PubMed ID: 18493996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chloroethylating and methylating dual function antineoplastic agents display superior cytotoxicity against repair proficient tumor cells.
    Zhu R; Baumann RP; Patridge E; Penketh PG; Shyam K; Ishiguro K; Sartorelli AC
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1853-9. PubMed ID: 23395657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
    Morris KL; Adams JA; Liu Yin JA
    Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
    Zheng LM; Li Z; Liu L; Song BL; King I
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male rats.
    Nassar AF; Wisnewski A; King I
    Xenobiotica; 2015; 45(8):711-21. PubMed ID: 25798740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.